Tyr Pharma has been able to make significant progress developing its lead clinical drug for the treatment of patients with pulmonary sarcoidosis. See why ATYR stock is a Buy.

Fidus Investment easily covered its base dividend with adjusted net investment income in Q2. Read why I think FDUS stock is a ...

Energy Fuels is increasing uranium production to 1.1-1.4mm pounds/year by end-2024. Read why I am rerating UUUU shares with a ...

Broadcom's stock skidded 10% on Friday despite strong Q3 earnings and a beat on the top/bottom line. See why I upgrade AVGO ...

Today's European markets saw declines, with Stoxx 600 down 0.50%. Bond yields also dropped, including U.S.

Modine has shown its increasing efficiency through two very important measures, ROIC and ROCE. These capital efficiency ...

Broadcom stock dropped 10% following a strong 3Q FY2024, driven by disappointing 4Q revenue guidance. See why I maintain my ...

Despite recent declines, company's strategic investments and position for growth make it a strong long-term buy.

Whitestone's recent performance has been very good, with meaningful projected NOI and core FFO increases for 2024. See why ...

The bears have emerged from their caves and are roaming widely. The biggest driver of the equity markets will be who is ...

Altria's transition to smoke-free products is crucial for sustaining its high dividend yield. Read why I give MO stock a ...

Tokyo Electron continues to ramp up its R&D spending and capital expenditures. Read why we will wait before seriously ...